Pyoderma Gangrenosum with Biological Agents Therapy: A Systematic Review

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Pyoderma gangrenosum (PG) is a rare, ulcerative skin condition with limited treatment options.
• Traditional therapies like glucocorticoids and immunosuppressants have significant adverse effects and variable efficacy.
• Biological agents, including TNF-α and IL inhibitors, are emerging as effective and safer alternatives for PG management.

Purpose of the Study:

• To systematically review and compare the treatment outcomes of TNF-α inhibitors and IL inhibitors in patients with pyoderma gangrenosum.
• To evaluate the efficacy and safety profiles of different biologic agents used in PG treatment.

Main Methods:

• A comprehensive literature search was conducted on PubMed, identifying 107 relevant studies.
• Systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
• Data from 139 patients treated with either TNF-α inhibitors (n=92) or IL inhibitors (n=47) were analyzed.

Main Results:

• Overall efficacy rates were high for both TNF-α inhibitors (88.0%) and IL inhibitors (93.6%), with no statistically significant difference (p>0.05).
• IL inhibitors demonstrated a shorter time to achieve partial or complete remission compared to TNF-α inhibitors.
• Specific agents like Infliximab (a TNF-α inhibitor) were associated with a higher number and variety of adverse events.

Conclusions:

• Both TNF-α and IL inhibitors are effective biologic treatments for pyoderma gangrenosum.
• IL inhibitors offer a potential advantage due to faster remission times and a potentially better safety profile.
• Infliximab requires cautious use due to its broader range of reported side effects.